ANSWER: C

Rationale:

Diltiazem is a non-dihydropyridine (non-DHP) calcium channel blocker (CCB) with significant negative inotropic effects — it reduces myocardial contractility in addition to slowing the ventricular rate (negative chronotropic and dromotropic effects). In this patient with HFpEF and preserved systolic function (LVEF 54%), diltiazem is an appropriate rate-control option because the ventricle's contractile reserve is intact; the negative inotropic effect does not carry the risk of precipitating hemodynamic collapse. However, if this patient's LVEF were 28% (HFrEF), diltiazem would be contraindicated: adding a negative inotropic agent to a ventricle with already severely impaired systolic function can precipitate acute decompensation and cardiogenic shock. This distinction — non-DHP CCBs are acceptable in HFpEF but contraindicated in HFrEF — is the clinically important pharmacological principle this scenario tests. Option A: Intravenous metoprolol tartrate is appropriate for acute rate control in both HFpEF and HFrEF with AF; beta-blockers do not carry the negative-inotropy contraindication specific to non-DHP CCBs and are the preferred rate-control agents in HFrEF. This would not be the agent that is appropriate in HFpEF but contraindicated in HFrEF. Option B: Carvedilol (a non-selective beta-blocker with alpha-1 blockade) is used for both rate control and HFrEF disease modification; it is not the agent differentiated by the HFpEF versus HFrEF distinction in this question. Option C: Correct. Diltiazem (a non-DHP CCB) is the agent appropriate in HFpEF (preserved systolic function) but contraindicated in HFrEF (impaired systolic function) due to its negative inotropic effects. Option D: Digoxin for adjunct rate control is used in both HFpEF and HFrEF; it is not the agent differentiated by the LVEF distinction in this scenario. Option E: Electrical cardioversion is a rhythm-control strategy, not a rate-control pharmacological agent, and is not the answer the question is testing. It may be considered in both HFpEF and HFrEF and is not contraindicated based on LVEF alone.

ANSWER: E

Rationale:

The 2022 AHA/ACC/HFSA guideline Class IIa recommendation for SGLT2 inhibitors in HFpEF applies to patients with LVEF typically above 40–45%, irrespective of diabetes status. The patient in Option E meets all appropriate criteria: LVEF 50% (within the HFpEF range), eGFR 42 mL/min/1.73m² (above the minimum threshold of approximately 20 mL/min/1.73m² for dapagliflozin and empagliflozin initiation in HF), no contraindications, and he is clinically stable (euvolemic on oral diuretics). Absence of diabetes does not preclude SGLT2 inhibitor use in HFpEF; the HF indication is independent of glycemic management. This patient represents the appropriate outpatient, stable, euvolemic HFpEF candidate. Option A: This patient has an eGFR of 18 mL/min/1.73m², which falls below the threshold for SGLT2 inhibitor initiation (dapagliflozin is approved for HF down to eGFR 25 mL/min/1.73m² in some approvals, but eGFR 18 represents advanced CKD stage 5 approaching dialysis — initiation is not recommended at this level). Caution is required at this eGFR, and this is not the best candidate. Option B: History of Fournier's gangrene (necrotizing fasciitis of the genitoperineal region — a rare but serious SGLT2 inhibitor-associated adverse effect) is a contraindication to re-initiation of any SGLT2 inhibitor. This patient should not receive this drug class. Option C: Acute decompensated heart failure requiring intravenous diuresis is not an appropriate clinical setting to initiate SGLT2 inhibitors. SGLT2 inhibitors should be started in a clinically stable, euvolemic patient; initiation during acute decompensation is not guideline-recommended for HFpEF. Option D: This patient's eGFR of 22 mL/min/1.73m² represents stage 5 CKD approaching dialysis threshold; initiation of SGLT2 inhibitors is not recommended at this eGFR. Additionally, she is volume-overloaded, which further argues against initiation at this time. Option E: Correct. LVEF 50%, eGFR 42, no diabetes, clinically stable and euvolemic — this patient meets all criteria for SGLT2 inhibitor initiation under the Class IIa HFpEF guideline recommendation.

ANSWER: B

Rationale:

This presentation — symptomatic hypotension and acute kidney injury (prerenal azotemia, as reflected by the creatinine rise) following aggressive diuresis in an HFpEF patient — is a direct clinical consequence of the preload dependence of the stiff, hypertrophied HFpEF ventricle. In HFrEF, the dilated ventricle can often tolerate aggressive decongestion because it operates on a flatter portion of the Starling curve; modest reductions in filling pressure do not steeply reduce stroke volume. In HFpEF, by contrast, the hypertrophied ventricle operates on the steep portion of a shifted pressure-volume relationship, meaning that small reductions in filling pressure produce disproportionately large reductions in stroke volume and cardiac output. When aggressive diuresis dropped filling pressures too far in this patient, cardiac output fell, systemic blood pressure dropped, and renal perfusion decreased — producing prerenal acute kidney injury. This is the canonical complication of over-diuresis in HFpEF and explains why euvolemia, not aggressive volume depletion, is the target in this population. Option A: Furosemide does not inhibit aldosterone synthesis, and HFpEF is not characterized by adrenal insufficiency requiring aldosterone support to maintain vascular tone. This option describes a fictitious mechanism. Option B: Correct. Preload dependence of the stiff HFpEF ventricle is the mechanistic explanation. Aggressive diuresis reduces filling pressure beyond the tolerable threshold, producing a steep fall in stroke volume, cardiac output, blood pressure, and renal perfusion. Option C: Sympathetic nervous system activation following volume depletion causes peripheral vasoconstriction but also typically increases heart rate and maintains — rather than reduces — blood pressure. Sympathetic activation in volume depletion is a compensatory response, not a mechanism of hypotension. Option D: Furosemide acts primarily at the Na-K-2Cl cotransporter in the loop of Henle; it does not inhibit renal prostaglandin synthesis at this site. NSAID-mediated prostaglandin inhibition is a distinct mechanism involving cyclooxygenase, not furosemide pharmacology. Option E: Furosemide produces a dilute urine (by blocking reabsorption at the loop of Henle); it can produce hyponatremia through various mechanisms but typically not in this acute time frame after a single aggressive diuresis period. The clinical picture here — orthostatic hypotension, creatinine rise — is most consistent with volume depletion and prerenal azotemia, not hyponatremia-driven vasodilation.

ANSWER: A

Rationale:

When amiodarone is added to a patient on digoxin, an immediate dose reduction is required. Amiodarone is a potent inhibitor of P-glycoprotein (P-gp), the membrane transporter responsible for renal tubular and intestinal secretion of digoxin. Inhibition of P-gp reduces digoxin elimination, causing serum digoxin levels to rise by approximately 50–100% over the following days to weeks. A digoxin level currently at 0.7 ng/mL (within the therapeutic range) could rise to approximately 1.2–1.4 ng/mL — approaching or entering the toxic range (toxicity increasingly likely above 2.0 ng/mL, with clinical vigilance appropriate at levels above 1.0–1.2 ng/mL) — if the dose is not reduced. The standard management is to halve the digoxin dose empirically at the time of amiodarone initiation, then recheck levels at 1–2 weeks to guide further titration. Option A: Correct. Empirical 50% dose reduction plus repeat level measurement is the required management step when amiodarone is added to a patient on digoxin, reflecting the P-gp inhibition mechanism that raises digoxin levels 50–100%. Option B: Amiodarone does not displace digoxin from Na-K-ATPase binding and does not reduce digoxin levels; the interaction raises digoxin levels. Increasing the dose would compound the toxicity risk. This option describes an incorrect mechanism and an incorrect clinical action. Option C: While avoiding the combination in some patients may be appropriate clinically, the question asks for the most important pharmacological management step regarding digoxin — which is dose reduction, not automatic discontinuation. Digoxin provides rate control through AV node slowing (via vagal and direct AV nodal effects) while amiodarone provides anti-arrhythmic rhythm control; the two drugs are not mechanistically redundant. Option D: The amiodarone–digoxin interaction is clinically significant at all doses of digoxin, including 0.125 mg daily. Continuing without dose adjustment carries a meaningful toxicity risk as levels accumulate over days to weeks. "Clinically insignificant at low doses" is incorrect. Option E: Potassium supplementation is an important supportive measure (hypokalemia does sensitize Na-K-ATPase to digoxin and lowers the toxicity threshold), but the primary and most urgent management step is the pharmacokinetic dose reduction to counteract P-gp inhibition. Potassium supplementation without dose reduction does not prevent the expected level rise.

ANSWER: D

Rationale:

This patient has been on GDMT for only 2 months. The guideline-mandated optimization period before primary prevention ICD implantation in newly diagnosed non-ischemic HFrEF is a minimum of 3 months. This waiting period exists precisely because GDMT — particularly the four-pillar combination of ARNI, beta-blocker, MRA, and SGLT2 inhibitor — can produce substantial LVEF recovery that may ultimately eliminate the ICD indication. This patient's LVEF has already improved from 25% to 32% in 2 months, suggesting ongoing favorable remodeling is occurring. Waiting the full 3-month period and then reassessing LVEF is both guideline-compliant and clinically rational: if the LVEF recovers above 35%, the primary prevention indication is no longer met and implantation was unnecessary. The correct action is continuation of the current GDMT regimen until the 3-month mark, then repeat LVEF assessment. Option A: Proceeding with ICD implantation at 2 months violates the guideline-mandated 3-month GDMT optimization period. The LVEF improvement trend suggests ongoing remodeling, and premature implantation may result in unnecessary device placement. Option B: Reducing GDMT from four pillars to three is not a guideline-recommended strategy for optimizing HFrEF management or assessing ICD candidacy. All four drugs should be continued at target doses; eplerenone discontinuation would be clinically counterproductive. Option C: A wearable cardioverter-defibrillator may be considered in specific clinical contexts (very high arrhythmic risk during GDMT optimization, such as newly diagnosed HFrEF with syncope), but it is not a guideline-mandated bridge to ICD in newly diagnosed non-ischemic HFrEF awaiting the optimization period. There is no clear evidence of high arrhythmic risk in this asymptomatic patient. Option D: Correct. Continue all four GDMT medications and reassess at the 3-month mark. The full optimization period has not yet been completed; LVEF improvement is ongoing; and guideline recommendations require 3 months of GDMT before ICD evaluation in non-ischemic HFrEF. Option E: Cardiac catheterization is not a required step in the ICD decision pathway for a patient who has already been classified as non-ischemic HFrEF. If non-ischemic etiology was established at diagnosis, repeat catheterization to re-verify is not indicated before device evaluation.

ANSWER: C

Rationale:

When ACE inhibitors (and by extension, all RAAS-blocking agents — ARBs and ARNIs) are contraindicated in pregnancy, the guideline-supported replacement for afterload reduction in the pregnant heart failure patient is the combination of hydralazine (a direct arterial vasodilator) plus a nitrate such as isosorbide dinitrate. Hydralazine reduces systemic vascular resistance (afterload), and isosorbide dinitrate reduces venous preload and may provide additional arterial vasodilation at higher doses. Together, they approximate the hemodynamic benefits of RAAS blockade without the teratogenic fetal RAAS-blockade syndrome (oligohydramnios, renal tubular dysgenesis, limb contractures) that makes ACEi and ARBs contraindicated throughout all trimesters of pregnancy. Hydralazine has a decades-long safety record in pregnancy hypertension and hypertensive crises in pre-eclampsia, and nitrates are considered safe in pregnancy at standard doses. Option A: Valsartan (an ARB) is contraindicated in pregnancy throughout all trimesters for the same reasons as ACEi — fetal RAAS-blockade syndrome. ARBs carry no differential safety advantage over ACEi in pregnancy; both drug classes are fully contraindicated. Option B: While amlodipine is used in pregnancy hypertension and is considered relatively safe, it is not the guideline-preferred afterload reducer specifically in the pregnant HFrEF patient requiring RAAS-blockade substitution. Hydralazine plus nitrate is the accepted pharmacological standard for this indication. Option C: Correct. Hydralazine plus isosorbide dinitrate is the recommended afterload-reducing combination when RAAS blockade is contraindicated in pregnancy. It provides arterial and venous vasodilation with an established pregnancy safety profile. Option D: Losartan is an ARB and is contraindicated throughout all trimesters of pregnancy. There is no ARB with a "favorable teratogenicity profile" in pregnancy; the entire drug class is contraindicated due to fetal RAAS-blockade effects. This option is pharmacologically incorrect. Option E: Spironolactone is contraindicated in pregnancy due to its anti-androgenic properties and the risk of feminization of a male fetus. It does not substitute for ACEi and is not a safe afterload-reducing agent in pregnancy.

ANSWER: E

Rationale:

Furosemide must reach the luminal side of the thick ascending limb of the loop of Henle to inhibit NKCC2 and produce diuresis. Because furosemide is approximately 98% protein-bound, it is largely excluded from the glomerular filtrate. Its route of entry into the tubular lumen is therefore active secretion by organic anion transporter 1 (OAT1) and OAT3 located in the proximal tubular cells. As CKD progresses and functioning nephron mass is lost, the aggregate proximal tubular secretory capacity for furosemide decreases proportionally. With less drug reaching the tubular lumen per dose, the natriuretic effect is blunted. This explains why furosemide doses that were previously effective become insufficient as CKD worsens, and why patients with advanced CKD require dramatically higher doses — sometimes 200–400 mg intravenously — to achieve the same intraluminal drug exposure that a 40–80 mg dose would provide in a patient with normal renal function. Option A: While uremic toxins do competitively displace furosemide from albumin binding at organic anion binding sites on albumin (which reduces the unbound fraction available for OAT secretion), this is a secondary contributor and does not fully explain the dose escalation requirement. The primary mechanism is loss of OAT-mediated secretory capacity from nephron loss, not inflammatory protein binding. Option B: NKCC2 downregulation in CKD is not an established pharmacological explanation for furosemide resistance. The primary mechanism of furosemide dose escalation in CKD is impaired drug delivery to the tubular lumen, not receptor loss at the loop of Henle. Option C: Furosemide's oral bioavailability in CKD is reduced but does not fall to near zero; it is approximately 40–70% in CKD (compared with the more consistent 80–100% bioavailability of torsemide). The principal reason for intravenous administration in acute decompensation is more reliable and faster absorption, not complete loss of oral bioavailability. Option D: Furosemide acts on the luminal surface of the NKCC2 cotransporter — it does not cross the tubular epithelium to reach an intracellular target. Urinary pH changes do not prevent furosemide from reaching its site of action, which is extracellular (luminal). Option E: Correct. OAT1/OAT3-mediated proximal tubular secretion is the mechanism of furosemide delivery to the tubular lumen; nephron loss in CKD reduces this secretory capacity proportionally, requiring dose escalation to achieve adequate intraluminal drug concentrations.

ANSWER: B

Rationale:

Two distinct and additive mechanisms are contributing to this patient's digoxin toxicity. First, CKD-related nephron loss reduces the renal clearance of digoxin (which is approximately 70% renally excreted unchanged), causing drug accumulation and elevated serum levels — the level of 1.6 ng/mL is significantly above the HF target range of 0.5–0.9 ng/mL even though 0.125 mg daily is considered a "low dose." Second, hypokalemia (potassium 3.3 mEq/L) independently lowers the threshold for digoxin toxicity by a distinct pharmacodynamic mechanism: potassium and digoxin compete for the same binding site on the alpha subunit of Na-K-ATPase. When extracellular potassium is low, the enzyme is less occupied by potassium and digoxin binds more readily — meaning digoxin's inhibitory effect on the pump is amplified at any given serum drug concentration. This patient therefore has both a pharmacokinetic cause of elevated digoxin levels (reduced renal elimination in CKD) and a pharmacodynamic cause of heightened toxicity risk (hypokalemia sensitizing Na-K-ATPase), creating a compounded and clinically serious situation. Option A: Digoxin is not significantly metabolized by CYP3A4; it is predominantly renally eliminated without meaningful hepatic biotransformation. CYP enzyme induction would not explain elevated digoxin levels. The hypokalemia is not unrelated — it is mechanistically linked to toxicity through Na-K-ATPase sensitization. Option B: Correct. Reduced renal elimination in CKD causes accumulation (pharmacokinetic), and hypokalemia sensitizes Na-K-ATPase to digoxin inhibition (pharmacodynamic) — both mechanisms are active and additive in this patient. Option C: Digoxin absorption is not meaningfully increased by CKD-related gut motility changes; its oral bioavailability is primarily determined by the drug formulation and is not substantially increased by CKD. Hypokalemia lowers the toxicity threshold through the Na-K-ATPase mechanism, not through action potential duration changes. Option D: Digoxin undergoes minimal hepatic glucuronidation; its elimination is primarily renal. Reduced hepatic metabolism is not a meaningful contributor to elevated levels in CKD. The mechanism of hypokalemia's effect is competition at Na-K-ATPase, not calcium channel modulation. Option E: Digoxin pharmacokinetics are meaningfully altered by CKD even at eGFR 30–45 mL/min/1.73m². At this level of renal impairment, digoxin clearance is substantially reduced compared with normal renal function, and dose reduction is clinically indicated. Attributing the elevated level entirely to hypokalemia is incorrect.

ANSWER: A

Rationale:

The primary clinical consequence of a subtherapeutic INR in an LVAD patient is device thrombosis. The LVAD mechanism creates a non-physiological blood-biomaterial interface that is inherently thrombogenic; therapeutic anticoagulation with warfarin (INR 2.0–3.0) is required to prevent clot formation within the pump inflow cannula and pump housing. When the INR falls below the therapeutic range (as in this patient with INR 1.4), the anticoagulant protection is insufficient, and thrombus can form within the device. LVAD thrombosis is a serious complication that may present as pump malfunction (reduced flow, increased power consumption, hemolysis markers), stroke from thrombus embolizing from the device, or acute hemodynamic collapse from complete pump failure. The dietary change — increased leafy green vegetable intake supplying vitamin K — reduces warfarin efficacy by supplying the substrate for the coagulation factors warfarin blocks, explaining the subtherapeutic INR. Management is warfarin dose adjustment and dietary counseling. Option A: Correct. Device thrombosis is the primary and most serious risk associated with subtherapeutic INR in an LVAD patient. The thrombogenic nature of the LVAD mechanism requires continuous therapeutic anticoagulation to prevent pump thrombus formation. Option B: Warfarin skin necrosis is a rare complication of warfarin initiation (not chronic subtherapeutic INR) caused by a transient hypercoagulable state from early protein C depletion. It occurs at the start of warfarin therapy, not from dietary vitamin K interactions reducing INR in a patient on established warfarin. Option C: Heparin-induced thrombocytopenia (HIT) occurs as an immune response to heparin-platelet factor 4 complexes and is not a consequence of a subtherapeutic warfarin INR. Standard management of subtherapeutic INR in a stable LVAD patient does not routinely require bridging with heparin. Option D: Subtherapeutic INR does not cause paradoxical factor Xa accumulation or increased bleeding risk. A low INR indicates under-anticoagulation with increased coagulation activity, not increased bleeding propensity. This option describes a fictitious mechanism. Option E: Mechanical hemolysis in LVAD patients is a known complication but is typically associated with pump thrombosis causing turbulent flow — it is a consequence of device thrombosis, not a primary risk of subtherapeutic anticoagulation itself. The primary risk is the thrombosis event, not hemolysis in isolation.

ANSWER: D

Rationale:

Spironolactone is contraindicated throughout pregnancy. Its pharmacological mechanism includes significant anti-androgenic activity — it blocks androgen receptors and reduces androgenic steroid synthesis — which is why it is effective in conditions involving androgen excess (polycystic ovary syndrome, hirsutism, primary hyperaldosteronism). During fetal development, androgens are required for normal differentiation of the male external genitalia, which occurs primarily between weeks 8 and 16 of gestation. Anti-androgenic drug exposure during this critical window carries the risk of feminization of a genetically male fetus — underdevelopment or abnormal development of male external genitalia. Two additional points make continuation unjustifiable: (1) the anti-androgenic risk is present at all therapeutic doses, not just high doses, because the androgen receptor blockade is the drug's pharmacological mechanism; and (2) although the risk is specific to male fetuses, fetal sex cannot be reliably determined early in the first trimester when the critical developmental window begins. Amiloride — a potassium-sparing diuretic that blocks the epithelial sodium channel (ENaC) rather than the mineralocorticoid receptor — lacks anti-androgenic activity and is considered a safer potassium-sparing alternative in pregnancy when such therapy is genuinely required. Option A: The anti-androgenic risk of spironolactone is not dose-dependent in a way that makes low doses safe in pregnancy. The drug blocks androgen receptors as part of its pharmacological mechanism at all therapeutic doses, including the 25 mg HFrEF dose. Dose reduction does not eliminate the fetal risk. Option B: Male fetal genital differentiation begins at approximately 8–10 weeks of gestation — within the first trimester — not the second trimester. This patient is already at 7 weeks; the critical developmental window is already approaching. Continuing through the first trimester does not adequately protect the fetus. Option C: While the anti-androgenic teratogenic risk is specific to male fetuses, fetal sex cannot be reliably determined at 7 weeks gestation. Waiting for fetal sexing at 12 weeks would expose a potentially male fetus through weeks 8–12 — precisely the critical window for male urogenital differentiation. This approach does not adequately mitigate the risk. Option D: Correct. Spironolactone is contraindicated throughout pregnancy at all doses due to anti-androgenic fetal risk; the risk cannot be mitigated by dose reduction, monitoring, or early fetal sexing. Amiloride is a pharmacologically appropriate potassium-sparing alternative without anti-androgenic activity. Option E: Spironolactone is contraindicated in pregnancy, not merely requiring increased surveillance. There is no monitoring protocol that renders its use in pregnancy acceptable; the recommendation is for discontinuation, not continued use with additional fetal imaging.

ANSWER: C

Rationale:

In cardiac resynchronization therapy (CRT) guidelines, QRS morphology is a critical determinant of indication strength. Left bundle branch block (LBBB) with QRS duration 150 ms or above carries a Class I indication for CRT in eligible HFrEF patients (LVEF 35% or below, NYHA II–IV, sinus rhythm) because randomized trial data consistently demonstrate mortality and morbidity benefit in this subgroup. Non-LBBB morphology (including RBBB, left anterior fascicular block, left posterior fascicular block, and non-specific intraventricular conduction delay) with QRS duration of 150 ms or above carries a Class IIa recommendation — "reasonable to consider" — reflecting a meaningful but less consistent evidence base compared with LBBB. Meta-analyses and subgroup analyses suggest that CRT benefit in non-LBBB patients is real but smaller and more heterogeneous. This patient — non-LBBB, QRS 155 ms, LVEF 28%, NYHA III, sinus rhythm, after 4 months of optimized GDMT — has a Class IIa CRT indication and is a reasonable CRT candidate, but her recommendation strength is lower than it would be if her morphology were LBBB. Option A: CRT is not contraindicated in non-LBBB morphology. It carries a Class IIa recommendation in non-LBBB patients with QRS 150 ms or above. Biventricular pacing can improve synchrony even in non-LBBB patterns, though the benefit is less consistent than in LBBB. Option B: Non-LBBB patients do not receive a Class I indication equivalent to LBBB patients. The evidence base for LBBB is stronger and more consistent, which is why guidelines differentiate the recommendation strength. QRS duration alone is not the sole determinant — morphology matters critically. Option C: Correct. Non-LBBB morphology with QRS 150 ms or above carries a Class IIa CRT recommendation in appropriate HFrEF patients. The evidence is meaningful but less robust than for LBBB, warranting a weaker but still favorable recommendation. Option D: His-bundle pacing is not mandated specifically for non-LBBB morphology patients; it is an emerging technique applicable to various CRT candidates and is not a guideline-required alternative to biventricular pacing in non-LBBB patients. Standard biventricular CRT remains acceptable in this clinical setting. Option E: CRT is not Class III in non-LBBB morphology; it is not contraindicated or considered harmful. A Class III designation would mean the procedure should not be performed. The actual guideline gives non-LBBB QRS 150 ms or above a Class IIa recommendation, meaning it is considered potentially beneficial.

ANSWER: E

Rationale:

Among the clinical features described, severe LVEF depression (22%) is the characteristic most directly and consistently linked to bromocriptine benefit in PPCM. The 2019 ESC position statement on PPCM (Bauersachs et al., European Journal of Heart Failure) gives bromocriptine a Class IIb recommendation in severe PPCM, with the severity threshold generally defined as LVEF below 25–30%. Pilot randomized controlled trial data from Germany (Sliwa et al.) demonstrated that bromocriptine-treated PPCM patients showed superior LVEF recovery compared with controls, with the greatest absolute benefit in those with severely reduced baseline LVEF. The proposed mechanism — suppression of the cardiotoxic 16-kDa prolactin fragment generated by oxidative stress cleavage — underpins the rationale. Critically, bromocriptine suppresses lactation, and this must be explicitly discussed with the patient before initiation, particularly given that this patient is currently breastfeeding. The breastfeeding status makes the informed consent discussion especially important, not a straightforward indication for treatment. Option A: Breastfeeding itself is not a clinical indication for bromocriptine in PPCM. While breastfeeding increases prolactin levels, bromocriptine use in a breastfeeding PPCM patient requires careful discussion of the trade-off: suppressing lactation in exchange for potential cardiac benefit. The severity of cardiac dysfunction — not breastfeeding status alone — is the clinical driver for the recommendation. Option B: The 3-week postpartum timing places the patient within the PPCM diagnostic window but does not specifically strengthen the indication for bromocriptine, which is based on disease severity (LVEF), not postpartum timing per se. Option C: Right ventricular involvement in PPCM is associated with worse prognosis, but there is no specific randomized trial evidence showing that right ventricular phenotype is the subgroup with greatest bromocriptine response. The evidence supporting bromocriptine is strongest in the severe LVEF depression subgroup. Option D: Family history of PPCM is not an established predictor of bromocriptine response and is not mentioned in the case. Prolactin-level variation is not reliably stratified by family history in current guidelines. Option E: Correct. Severe LVEF depression (22%) is the clinical feature most directly supported by the ESC Class IIb recommendation for bromocriptine in severe PPCM. This, combined with the need for informed discussion about lactation suppression, represents the full clinical picture for bromocriptine consideration in this patient.

ANSWER: B

Rationale:

This patient — obese HFpEF (BMI 41 kg/m², LVEF 54%) on an SGLT2 inhibitor but still symptomatic — is the ideal candidate for semaglutide, a GLP-1 receptor agonist. The STEP-HFpEF trial evaluated semaglutide 2.4 mg weekly (the weight-management dose) in HFpEF patients with obesity (BMI 30 kg/m² or above) and demonstrated significant improvements in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores (symptom burden and quality of life), 6-minute walk distance, and composite HF events — exactly the endpoints most relevant to this patient's ongoing symptoms. The mechanism in obese HFpEF includes substantial weight reduction (reducing epicardial fat, pericardial constraint, and the pro-inflammatory adiposity burden driving HFpEF), as well as potential direct cardiac and metabolic effects. The 2023 guideline update gave semaglutide a Class IIa recommendation in obese HFpEF (BMI 30 kg/m² or above), making it the most evidence-supported add-on in this patient's phenotype. The SGLT2 inhibitor and GLP-1 agonist have complementary and additive mechanisms, and the combination is appropriate. Option A: Spironolactone (MRA) carries a Class IIb recommendation in carefully selected HFpEF patients based on TOPCAT data, but it is a weaker recommendation than semaglutide's Class IIa in this specific obese phenotype. It does not address the dominant pathophysiological driver (adiposity) in this patient and is not the most evidence-supported next step here. Option B: Correct. Semaglutide has a Class IIa recommendation in obese HFpEF, is supported by STEP-HFpEF randomized trial data, and directly targets the dominant pathophysiological driver (obesity) in this patient's HFpEF phenotype. Option C: Sacubitril/valsartan carries a Class IIb recommendation in HFpEF with LVEF below normal (based on PARAGON-HF post-hoc data), not a Class I recommendation. Additionally, this patient is already on an ACEi (lisinopril); sacubitril/valsartan replaces RAAS blockade but would require stopping lisinopril and a washout period. It is not the most evidence-supported add-on for an obese HFpEF patient still symptomatic on SGLT2 inhibitor. Option D: Metformin is used for glycemic control in this patient's type 2 diabetes but has no established Class IIa guideline recommendation as a disease-modifying HFpEF treatment. Its AMPK-based mechanistic rationale has not been validated in a large randomized HFpEF trial demonstrating primary endpoint benefit. Option E: Ivermectin is an antiparasitic drug, not a cardiac myosin inhibitor. Mavacamten is the selective cardiac myosin inhibitor approved for hypertrophic cardiomyopathy (HCM), not for HFpEF with concentric hypertrophy. This option contains factual errors and describes a non-existent HFpEF indication.

ANSWER: A

Rationale:

Carvedilol and other beta-blockers cross the placenta and produce pharmacological effects in the fetus and neonate through the same receptor-mediated mechanisms that operate in adults. The two primary neonatal complications to monitor for are: (1) bradycardia — from beta-1 adrenergic receptor blockade in the fetal cardiac conduction system, which can manifest as a persistently low heart rate in the neonate (neonatal bradycardia is defined as heart rate below 100 beats/minute); and (2) hypoglycemia — from beta-2 adrenergic receptor blockade impairing the sympathoadrenal response to hypoglycemia. Normally, epinephrine stimulates hepatic glycogenolysis and gluconeogenesis via beta-2 receptors to maintain blood glucose; beta-blockade suppresses this response, reducing the neonate's capacity to mobilize glucose stores and predisposing to symptomatic hypoglycemia in the first 24–48 hours of life. Both complications are manageable with standard neonatal monitoring (continuous cardiac monitoring, serial blood glucose checks), but the pediatric team must be alerted to the maternal medication exposure so appropriate surveillance is initiated. Option A: Correct. Neonatal bradycardia (beta-1 blockade) and neonatal hypoglycemia (beta-2 blockade of glycogenolysis/gluconeogenesis) are the established transplacental carvedilol effects requiring monitoring in the immediate postnatal period. Option B: Beta-2 adrenergic receptors on type II pneumocytes do influence surfactant release (beta-agonists, such as terbutaline, stimulate surfactant production), but carvedilol's transplacental exposure does not reliably produce respiratory distress syndrome in term neonates. This is not an established or expected complication of maternal beta-blocker use at term. Option C: Carvedilol does not block TSH receptor signaling. TSH receptors are G-protein coupled receptors in the thyroid gland, not beta-adrenergic receptors. Carvedilol's beta-blocking mechanism does not produce neonatal hypothyroidism. This option describes a fictitious pharmacological mechanism. Option D: QT prolongation is not an established neonatal complication of maternal carvedilol exposure. Carvedilol is a beta-blocker and alpha-1 blocker; it does not prolong the QT interval through potassium channel effects in adults or neonates. QT prolongation is associated with other drug classes (class III antiarrhythmics, certain antibiotics, antipsychotics). Option E: Carvedilol does not suppress ACTH secretion through central beta-2 blockade. The hypothalamic-pituitary-adrenal axis is not significantly regulated by beta-adrenergic receptors in a way that would produce neonatal adrenal insufficiency. This option describes a fictitious mechanism.

ANSWER: D

Rationale:

The standard safety threshold for MRA initiation in HFrEF is a serum potassium below 5.0 mEq/L. This patient's potassium of 5.2 mEq/L exceeds this threshold, making MRA initiation unsafe at this time. Adding an MRA (either spironolactone or eplerenone) when potassium is already above 5.0 mEq/L in a patient with CKD and on sacubitril/valsartan (which contains valsartan, a RAAS blocker that also raises potassium) carries a significant risk of clinically dangerous hyperkalemia (potassium 5.5–6.0 mEq/L or above), which can produce life-threatening cardiac arrhythmias. The appropriate strategy is to first lower potassium below 5.0 mEq/L before initiating MRA therapy. This can be achieved through: (1) dietary potassium restriction (reducing high-potassium foods such as bananas, oranges, potatoes, and dairy); (2) ensuring the SGLT2 inhibitor is at target dose (dapagliflozin's modest potassium-lowering effect may help); or (3) initiating a potassium binder such as patiromer (Veltassa) or sodium zirconium cyclosilicate (Lokelma), which bind potassium in the gastrointestinal tract and lower serum levels, creating a pharmacological window for MRA initiation in otherwise eligible HFrEF-CKD patients. Option A: A potassium of 5.2 mEq/L is not acceptable for MRA initiation; the guideline threshold is below 5.0 mEq/L. Initiating an MRA at 5.2 mEq/L in a patient with CKD and concurrent RAAS blockade creates substantial hyperkalemia risk. "Well tolerated" mild hyperkalemia does not apply to this specific clinical situation. Option B: While SGLT2 inhibitors have a modest potassium-lowering effect (through osmotic diuresis and natriuresis), this effect is not sufficiently reliable or rapid to justify MRA initiation against a baseline potassium of 5.2 mEq/L. The SGLT2 inhibitor potassium effect cannot be used as a pharmacological safety guarantee to override the 5.0 mEq/L initiation threshold. Option C: Permanent deferral is not the correct approach. MRA therapy has demonstrated mortality and HF hospitalization benefit in HFrEF and should be pursued in eligible patients. CKD stage 3a with eGFR 48 mL/min/1.73m² is well above the eGFR 30 mL/min/1.73m² threshold for MRA use; the barrier here is hyperkalemia, which is potentially reversible with the strategies described above. Option D: Correct. Potassium above 5.0 mEq/L is a contraindication to MRA initiation. Lower potassium below this threshold through dietary restriction, SGLT2 inhibitor optimization, or potassium binder therapy, then initiate MRA. Option E: Adding amiloride (itself a potassium-sparing diuretic — it blocks ENaC and therefore also causes potassium retention) to counteract eplerenone's potassium-retaining effects is pharmacologically incorrect. Amiloride does not lower potassium; it raises it. This combination would compound hyperkalemia risk rather than neutralize it.

ANSWER: C

Rationale:

The correct management is immediate discontinuation of naproxen, and the mechanistic explanation is NSAID-mediated disruption of prostaglandin-dependent renal autoregulation in the HFrEF-CKD setting. In a patient with combined HFrEF and CKD, renal perfusion is already compromised by reduced cardiac output and neurohormonal vasoconstriction (angiotensin II and norepinephrine predominantly constricting the efferent arteriole). In this state of reduced renal perfusion, the kidney compensates by producing prostaglandins (principally PGE₂ and PGI₂) locally, which dilate the afferent arteriole and preserve glomerular filtration pressure. NSAIDs inhibit cyclooxygenase (COX-1 and COX-2), blocking prostaglandin synthesis throughout the body including the kidney. When prostaglandin-mediated afferent vasodilation is lost, glomerular perfusion pressure falls sharply — producing a functional (prerenal) acute kidney injury, as reflected by the creatinine rise from 1.4 to 2.3 mg/dL. Simultaneously, reduced prostaglandin synthesis impairs tubular fluid delivery, worsening diuretic resistance and contributing to sodium and water retention (reflected in the 4-kg weight gain). NSAIDs are contraindicated in HFrEF-CKD regardless of eGFR level; there is no "safe" eGFR threshold above which NSAIDs become permissible in this combination. Option A: The creatinine rise temporally correlates directly with naproxen initiation 3 weeks prior. Attributing it to contrast nephropathy from an unspecified prior imaging study is clinically indefensible when the timeline strongly implicates the NSAID. Continuing naproxen with gastroprotection does not address the renal mechanism of harm. Option B: COX-2 selective NSAIDs (celecoxib) do affect renal prostaglandin synthesis — renal prostaglandins are produced through both COX-1 and COX-2 pathways. Celecoxib is not safe in HFrEF-CKD patients for the same mechanistic reasons as non-selective NSAIDs; switching to a COX-2 inhibitor does not resolve the renal risk in this population. Option C: Correct. Immediate NSAID discontinuation is required, and the mechanism is prostaglandin-dependent renal afferent arteriolar dilation being abolished by cyclooxygenase inhibition — producing prerenal AKI and diuretic resistance in the HFrEF-CKD setting. Option D: Dose reduction of naproxen does not eliminate its cyclooxygenase inhibition and the associated prostaglandin suppression in the kidney. The renal harm in HFrEF-CKD is a class effect of NSAIDs at all doses; dose adjustment cannot make the drug safe in this clinical context. Option E: NSAIDs are contraindicated in HFrEF-CKD at all eGFR levels above the dialysis threshold; there is no guideline-defined eGFR cutoff (such as 30 mL/min/1.73m²) above which NSAIDs become acceptable in this combination. The contraindication is based on the hemodynamic mechanism of renal harm, which is present regardless of eGFR.